Page last updated: 2024-08-24

web 2086 and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

web 2086 has been researched along with (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J	1

Trials

1 trial(s) available for web 2086 and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

Article	Year
The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:5 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Azepines; Beclomethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Platelet Activating Factor; Triazoles	1994

Article

Year

The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma.

American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:5

Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Azepines; Beclomethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Platelet Activating Factor; Triazoles

1994